Shots:
- UCB has reported the P-III (BE BOLD) trial data assessing Bimzelx vs risankizumab in 553 adults with active psoriatic arthritis, who are either biologic-naïve or were treated with TNF inhibitor with an inadequate or intolerant response
- Trial met its 1EP, showing superiority over risankizumab in reducing disease activity, as measured by ACR50, at Wk. 16; full data to be presented at a future congress
- Bimzelx is a humanized monoclonal IgG1 antibody designed to selectively inhibit interleukin-17A & interleukin-17F for the treatment of inflammatory diseases
Ref: PRnewswire | Image: UCB | Press Release
Related News: Antengene and UCB Strike ~$1.18B Deal to Advance ATG-201 for B-Cell–Related Autoimmune Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
